Aprea Therapeutics
APRE
24 hedge funds and large institutions have $10.8M invested in Aprea Therapeutics in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.
147% more capital invested
Capital invested by funds: $4.36M → $10.8M (+$6.41M)
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
20% more funds holding
Funds holding: 20 → 24 (+4)
18.68% more ownership
Funds ownership: 24.78% → 43.46% (+19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.68M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.28M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.18M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$853K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$505K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$410K |
| 2 |
Walleye Capital
New York
|
-$376K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$258K |
| 4 |
SCM
Sio Capital Management
New York
|
-$21.1K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$10.5K |
APRE Hedge Fund Activity: Q1 2024 in Review
24 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q1 2024, worth a combined $10.8M — up 147% from $4.36M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new APRE positions and 3 closed out — a net gain of 4 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $1.68M. The largest seller was Worth Venture Partners, exiting entirely with an estimated $410K sold.
- 24 institutional investors held Aprea Therapeutics (APRE) as of Q1 2024, up from 20 in Q4 2023.
- Funds reported $10.8M of Aprea Therapeutics stock for Q1 2024, up 147% quarter-over-quarter.
- 7 funds opened new Aprea Therapeutics positions in Q1 2024 and 3 closed out, a net change of +4 holders.
- The largest Aprea Therapeutics buyer in Q1 2024 was Sphera Funds Management, an estimated $1.68M added.
- The largest Aprea Therapeutics seller in Q1 2024 was Worth Venture Partners, an estimated $410K sold.
Based on aggregated 13F filings for Q1 2024.